HOTH logo

Hoth Therapeutics (HOTH) Company Overview

Profile

Full Name:

Hoth Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 15, 2019

Indexes:

Not included

Description:

Hoth Therapeutics is a biopharmaceutical company focused on developing innovative treatments for skin diseases and other medical conditions. They aim to improve patient care through advanced therapies, including their unique drug delivery systems and research on new compounds for effective treatment options.

Events Calendar

Earnings

Next earnings date:

May 14, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 26, 2022

Analyst ratings

Recent major analysts updates

Mar 4, 25 D. Boral Capital
Buy
Feb 11, 25 D. Boral Capital
Buy
Jan 23, 25 HC Wainwright & Co.
Buy
Jan 22, 25 HC Wainwright & Co.
Buy
Jan 7, 25 D. Boral Capital
Buy
Nov 4, 24 HC Wainwright & Co.
Buy
Aug 16, 24 HC Wainwright & Co.
Buy
Jul 26, 24 HC Wainwright & Co.
Buy
Jul 22, 24 HC Wainwright & Co.
Buy
Apr 5, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Hoth Therapeutics?
  • Does Hoth Therapeutics pay dividends?
  • What sector is Hoth Therapeutics in?
  • What industry is Hoth Therapeutics in?
  • What country is Hoth Therapeutics based in?
  • When did Hoth Therapeutics go public?
  • Is Hoth Therapeutics in the S&P 500?
  • Is Hoth Therapeutics in the NASDAQ 100?
  • Is Hoth Therapeutics in the Dow Jones?
  • When was Hoth Therapeutics's last earnings report?
  • When does Hoth Therapeutics report earnings?
  • Should I buy Hoth Therapeutics stock now?

What is the ticker symbol for Hoth Therapeutics?

The ticker symbol for Hoth Therapeutics is NASDAQ:HOTH

Does Hoth Therapeutics pay dividends?

No, Hoth Therapeutics does not pay dividends

What sector is Hoth Therapeutics in?

Hoth Therapeutics is in the Healthcare sector

What industry is Hoth Therapeutics in?

Hoth Therapeutics is in the Biotechnology industry

What country is Hoth Therapeutics based in?

Hoth Therapeutics is headquartered in United States

When did Hoth Therapeutics go public?

Hoth Therapeutics's initial public offering (IPO) was on February 15, 2019

Is Hoth Therapeutics in the S&P 500?

No, Hoth Therapeutics is not included in the S&P 500 index

Is Hoth Therapeutics in the NASDAQ 100?

No, Hoth Therapeutics is not included in the NASDAQ 100 index

Is Hoth Therapeutics in the Dow Jones?

No, Hoth Therapeutics is not included in the Dow Jones index

When was Hoth Therapeutics's last earnings report?

Hoth Therapeutics's most recent earnings report was on Nov 12, 2024

When does Hoth Therapeutics report earnings?

The next expected earnings date for Hoth Therapeutics is May 14, 2025

Should I buy Hoth Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions